

Ref. No: 240
From: Public
Date: 11/01/23
Subject: intra-vitreous injections or implants

REQUEST & RESPONSE

I am analysing the usage of intra-vitreous injections or implants by the NHS. I would greatly appreciate if you could answer the following questions:

1. How many of the following intra-vitreous injections / implants has your Trust administered in the four-month period from September to December 2022:

Treatment	No. Administered
Aflibercept	198
Bevacizumab	0
Brolucizumab	<5
Dexamethasone	11
Faricimab	0
Ranibizumab – Lucentis	768
Ranibizumab – Ongavia	0

2. Please provide the number of injections / implants by eye condition for the four-month period from September to December 2022.

Treatment	Wet Age-Related Macular Degeneration (wAMD)	Diabetic Macular Oedema (DMO)	Retinal Vein Occlusion (RVO)
Aflibercept	172	11	12
Bevacizumab	0	0	0
Brolucizumab	<5	0	0
Faricimab	0	0	0
Ranibizumab – Lucentis	527	67	146
Ranibizumab – Ongavia	0	0	0

Please note <5 has been added where the number of individuals is 5 or less, this information has been redacted to protect the confidentiality of individuals and to ensure that they cannot be identified.

Furthermore, please note that we are unable to provide the figures for Dexamethasone in response to question two. This is because the low figures, when combined with the response provided to question one, would enable the identification of low numbers.